Skip to main navigation
  • Careers
  • Contact Us
  • About Us
    • Corporate Governance
    • Executive Leadership
    • Board of Directors
    • Sustainability
    • Ethics & Integrity
  • News & Events
    • Press Releases
    • Events & Presentations
  • Investors
    • Investor Kit
    • Stock Information
    • Financials
    • SEC Filings
  • Therapeutic Areas
    • Cardiopulmonary
    • Difficult-to-Treat Depression
    • Drug-Resistant Epilepsy

    Q1 2026

    • Read more about Q1 2026

    Q4 2025

    • Read more about Q4 2025

    Q3 2025

    • Read more about Q3 2025

    Q2 2025

    • Read more about Q2 2025

    Q1 2025

    • Read more about Q1 2025

    Q4 2024

    • Read more about Q4 2024

    Q3 2024

    • Read more about Q3 2024

    Q2 2024

    • Read more about Q2 2024

    Q1 2024

    • Read more about Q1 2024

    Q4 2023

    • Read more about Q4 2023

    Pagination

    • Page 1
    • Next page ››
    Subscribe to Quarterly Results

    Our Company

    • About Us
    • News

    Therapeutic Areas

    • Cardiopulmonary
    • Drug-Resistant Epilepsy
    • Difficult-to-Treat Depression

    Contact Us

    • Customer Service
    • Commercial Sponsorship
    • Donations and Grants
    • Investigator-Initiated Research

    Transparency

    • Modern Slavery Statement
    • Carbon Reduction Plan
    • Conflict Minerals
    • © 2026 LivaNova PLC

    • Careers
    • Investors
    • Terms of Use
    • Privacy Policy
    • Washington Nevada Consumer Health Data
    • Cybersecurity
    • Patents
    • Cookie Policy
    • Cookie Settings

    LivaNova PLC - Registered in England and Wales - Registered No. 09451374 - 20 Eastbourne Terrace, London, W2 6LG, United Kingdom

    Top